CBRH7919 Cells

The CBRH7919 cell line is a rat hepatoma model frequently utilized in cancer research to investigate liver cancer mechanisms and therapeutic interventions. Derived from hepatocellular carcinoma in rats, these cells are characterized by their rapid proliferation and serve as a useful model for studying hepatocarcinogenesis and liver-specific metabolic functions. Recent studies have highlighted the CBRH7919 cell line’s involvement in evaluating the effects of various bioactive compounds on tumor cell growth and signaling pathways.

One significant area of research involving CBRH7919 cells includes the exploration of how natural compounds impact cell proliferation and apoptosis. For instance, choline plasmalogens (ChoPlas) extracted from swine liver have been shown to inhibit the proliferation of CBRH7919 cells. Mechanistically, ChoPlas treatment was found to increase Caveolin-1 expression while reducing phospho-Akt (pAkt) and Bcl-2 levels, thus influencing the PI3K/Akt signaling pathway. This modulation leads to cell cycle arrest at the G1/S transition, accompanied by a decrease in cyclin-dependent kinases (CDK2, CDK4) and cyclins E and D, which are crucial regulators of cell cycle progression.

Additional research has linked the expression of specific proteins like fudenine to metabolic regulation in CBRH7919 cells. Fudenine, a truncated rat homologue of mouse prominin, is reported to be upregulated under high glucose conditions and can increase GAPDH expression in CBRH7919 cells. This suggests that fudenine could play a role in glucose metabolism and potentially influence cellular energy dynamics and stress responses, making CBRH7919 cells a valuable model for diabetes and metabolism-related cancer research.